Factors influencing blood tumor marker concentrations in the absence of neoplasia
Authors:
- on behalf of Oncology Biomarkers Section of the Catalan Association of Clinical Laboratory ScienceOSon behalf of Oncology Biomarkers Section of the Catalan Association of Clinical Laboratory Science
Open Access
- 14 January 2024
- journal article
- review article
- Published by SAGE Publications in Tumor Biology
- Vol. 46 (s1) , S35-S63
Abstract
BACKGROUND: Tumor markers (TMs) are a heterogeneous group of molecules used in the diagnosis, prognosis and follow-up of cancer patients. During neoplastic differentiation, cells can either directly synthesize or induce the synthesis of TMs, and the release of these molecules into the bloodstream allows their quantification in biological fluids. Although very small concentrations of TMs are usually present in the serum or plasma of healthy subjects, increased concentrations may also be found in the presence of benign diseases or due to technical interference, producing false positive results. MATERIAL AND METHODS AND RESULTS: Our review analyses the causes of false positives described between January 1970 to February 2023 for the TMs most frequently used in clinical practice: α-fetoprotein (AFP), β2-microglobulin (β2-M), cancer antigen 15-3 (CA 15-3), cancer antigen CA 19-9 (CA 19-9), cancer antigen CA 72-4 (CA 72-4), cancer antigen 125 (CA 125), carcinoembryonic antigen (CEA), chromogranin A (CgA), choriogonadotropin (hCG), cytokeratin 19 fragment (CYFRA 21-1), neuron-specific enolase (NSE), human epididymis protein 4 (HE4), serum HER2 (sHER2), squamous cell carcinoma antigen (SCCA), protein induced by vitamin K absence-II (PIVKA-II), Pro-gastrin-releasing peptide (Pro-GRP), prostate-specific antigen (PSA), Protein S-100 (S-100) and thyroglobulin (Tg). A total of 247 references were included. CONCLUSIONS: A better understanding of pathophysiological processes and other conditions that affect the concentration of TMs might improve the interpretation of results and their clinical application.Keywords
This publication has 209 references indexed in Scilit:
- Alpha‐fetoprotein and focal nodular hyperplasia: An unconventional coupleJGH Open, 2021
- Effect of the coronavirus pandemic on tumor markersJournal of Medical Virology, 2021
- Elevations of serum cancer biomarkers correlate with severity of COVID‐19Journal of Medical Virology, 2020
- Plasma chromogranin a in patients with inflammatory bowel diseaseInflammatory Bowel Diseases, 2009
- Elevation of CA 19‐9 and chromogranin A, in addition to CA 125, are detectable in benign tumors in leiomyomas and endometriosisJournal of Clinical Laboratory Analysis, 2007
- G-CSF induces elevation of circulating CA 15-3 in breast carcinoma patients treated in an adjuvant settingCancer, 2001
- Maternal serum prostate-specific antigen and Down syndrome in the first and second trimesters of pregnancyPrenatal Diagnosis, 1999
- Evaluation of serum markers of neuronal damage following severe hypoglycaemia in adults with insulin-treated diabetes mellitusDiabetes/Metabolism Research and Reviews, 1999
- Prostate-specific antigen detection by ultrasensitive assay in samples from womenThe Prostate, 1996
- Prostate‐Specific antigen expression by various tumorsJournal of Clinical Laboratory Analysis, 1995